Welsh Government

Targeted treatments for cancers of the blood

Facilitator:  Elaine Vickers / Science Communicated 

Course outline: 

This course introduces the scientific concepts behind the new generation of targeted treatments for leukaemia, lymphoma and multiple myeloma. Elaine describes the genetic and molecular defects that underlie these cancers in order to explain the treatments that target them. Teaching sessions are supplemented with work sheets and exercises. 

The course is designed for research nurses and clinical trials staff therefore places are limited to those working on Health and Care Research Wales portfolio studies. 

Topics include:

  • the unique genetic and cellular features of haematological cancer cells;
  • CD antigens as targets for monoclonal antibody treatments such as rituximab, obinutuzumab, ofatumumab and brentuximab vedotin;
  • drugs that target signalling pathways controlled by FLT3, KIT, JAK2 and the B Cell Receptor;
  • the reasoning behind specific drugs for leukaemias, lymphomas and multiple myeloma;
  • the importance of biomarkers and patient selection.

Please note a certificate of attendance will only be issued if delegates complete all elements of the training. Times will be confirmed on receipt of the registration form.

Following the training, participants will be able to:

  • understand key concepts in cell biology and genetics;
  • describe why haematological cancers occur;
  • have improved knowledge about the range of targeted treatments for blood cancers and their mechanism of action;
  • recognise the potential for the personalisation of cancer treatment using genetic analysis and biomarkers.